Evidence map›Paper›PMID 30028555›Full record

ArticleCell proliferation2018

Vasoactive intestinal peptide induces proliferation of human hepatocytes.

M E M S Khedr, A M Abdelmotelb, T A Bedwell, A Shtaya, M N Alzoubi, M Abu Hilal, S I Khakoo

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell proliferation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

M E M S KhedrClinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0001-9942-4409
A M AbdelmotelbClinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0001-5911-2144
T A BedwellClinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0002-0139-6583
A ShtayaSt George's University of London, London, UK.ORCID http://orcid.org/0000-0001-7459-8437
M N AlzoubiClinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0003-3268-7938
M Abu HilalClinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0002-7900-3348
S I KhakooClinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0002-4057-9091
University of Southampton · GBSt George's, University of London · GBSuez Canal University · EGTanta University · EGUniversity of Jordan · JO

Funding

Liver and Pancreatic Research & Development Cancer Charity, Southampton, UKUniversity of Southampton, UK
6 · The paper itself

Abstract

objectivesProliferation of hepatocytes in vitro can be stimulated by growth factors such as epidermal growth factor (EGF), but the role of vasoactive intestinal peptide (VIP) remains unclear. We have investigated the effect of VIP on maintenance and proliferation of human hepatocytes. MATERIALS AND

methodsHuman hepatocytes were isolated from liver specimens obtained from patients undergoing liver surgery. Treatment with VIP or EGF was started 24 h after plating and continued for 3 or 5 d. DNA replication was investigated by Bromodeoxyuridine (BrdU) incorporation and cell viability detected by MTT assay. Cell lysate was analysed by western blotting and RT-PCR. Urea and albumin secretion into the culture supernatants were measured.

resultsVIP increased DNA replication in hepatocytes in a dose-dependant manner, with a peak response at day 3 of treatment. VIP treatment was associated with an increase in mRNA expression of antigen identified by monoclonal antibody Ki-67 (MKI-67) and Histone Cluster 3 (H3) genes. Western blotting analysis showed that VIP can induce a PKA/B-Raf dependant phosphorylation of extracellular signal-regulated kinases (ERK). Although EGF can maintain hepatocyte functions up to day 5, no marked efffect was found with VIP.

conclusionsVIP induces proliferation of human hepatocytes with little or no effect on hepatocyte differentiation. Further investigation of the role of VIP is required to determine if it may ultimately support therapeutic approaches of liver disease.

Indexed as

AdultAgedAged, 80 and overCell DifferentiationCell ProliferationCells, CulturedCell SurvivalDNA ReplicationEpidermal Growth FactorFemaleHepatocytesHumansKi-67 AntigenLiverMaleMiddle AgedEpidermal Growth FactorKi-67 AntigenMitogen-Activated Protein KinasesRNA, MessengerVasoactive Intestinal Peptide

Identifiers

PMID30028555
PMCPMC6528893
OpenAlexW2884592941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.